The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta
Abstract
Authors
D Paolicelli S Iannazzo L Santoni M D’Onghia V Direnzo A Iaffaldano E Puma V Di Lecce M Trojano